pharma · Oral Mucositis · Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
CSL Behring GmbH
CSL Behring is a pharma organization headquartered in Marburg, DE. Primary therapeutic focus areas include Oral Mucositis, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Rheumatoid Arthritis, Antibody-mediat
Marburg, DE HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- Marburg, DE
- Programs
- 7
- Drugs
- 6
- Patents
- 25
human immunoglobulin G
Phase 3 · small molecule · Dermatomyositis
human immunoglobulin G for Dermatomyositis is a Phase 3 program (small_molecule) at CSL Behring GmbH with 1 ClinicalTrials.gov record(s).
Internal code IgPro20_3007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CSL Behring GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Dermatomyositis
- Status
- terminated
- Trials
- 1